Other news to note for March 24, 2020

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Acadia, Adaptive, Allovir, Amneal, Aqualung, Arrowhead, Biontech, Cannabics, Cellenkos, Celltex, Cel-Sci, Codexis, Cytocom, Eli Lilly, Entos, E-therapeutics, Fujifilm, Fujitsu, Generex, Geovax Labs, Ibio, Immix, Immune, Junshi, Mannkind, Moleculin, Montreal Heart Institute, Nascent, Neoimmunetech, Neuren, Novan, Olix, Pfizer, Pharnext, Pluristem, Polarisqb, Regeneron, Resverlogix, Revive, Ribomic, Roche, Roivant, Signpath, Smartpharm, Soligenix, Sorrento, Sosei, Stabilitech, Takeda, Tarveda, Ubix, Vaxart, Vaxxas, WPD, Ziphius.

Financings for March 24, 2020

Biopharmas in Asia-Pacific raising money in public or private financings, including: IMV, Lattice Biologics, Tiziana Life Sciences.

Appointments and advancements for March 24, 2020

New hires and promotions in the biopharma industry in Asia-Pacific, including: Epimab Biotherapeutics, I-Mab Biopharma, Sumitomo Dainippon Pharma.

Regulatory front for March 24, 2020

The latest global regulatory news, changes and updates affecting biopharma, including: 340B Health, Department of Health and Human Services, FDA, Health Resources and Services Administration, Institute for Clinical and Economic Review, Medicines and Healthcare products Regulatory Agency.

Clinical data for March 17-24, 2020

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Algernon, Cytodyn, Genentech, Humanigen, Immutep, Inxmed (Shanghai) Co., Recce.

Regulatory actions for March 17-24, 2020

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Anheart, Applied DNA Sciences, Astrazeneca, Bellerophon, Can-Fite, Cansino Biologics, Cytodyn, Genentech, Hansoh, Merck, Novartis, Synairgen, Takis.